The overall objective of this research is to create a new drug delivery system
using polymeric micelles. The overall research is split up into four parts:
(1) Synthesis of amphiphilic polymers
(2) Finding and purifying the appropriate small molecule drug
(3) Encapsulation of the small drug in the polymeric micelle
(4) Release of the small drug from the polymeric micelle.
The summer research specifically dealt with steps (2) and (4) of the overall
research. The small molecule drug “Indometacin” was successfully purified and
exemplified a “burst release” from the PEG-Glu100-Leu100 polymer.

The polymer PEG-Glu100-Leu100 (Figure 2) was synthesized by David Ulkoski and used
to gather data on the encapsulation and release of indometacin. Other polymers have
been synthesized and future work will analyze encapsulation and release data.

Mylan 147 (Figure 3), which contains 50 mg of indometacin (Figure 4), is prescribed to
reduce fever, pain, stiffness, and swelling. About 85% of Mylan is filler, therefore
purification of indometacin from Mylan is necessary.

Figure 3: Mylan 147
capsule
Drug delivery systems are created to administer a pharmaceutical compound while
modifying its release profile, absorption, distribution, and elimination. An appropriate
drug delivery system improves the efficiency and safety of the drug, while providing the
patient with comfort and convenience. Examples of common drug delivery routes
include non-invasive peroral (by the mouth), topical (skin), transmucosal (nasal,
buccal/sublingual, vaginal, ocular and rectal), and inhalation routes. Research on
alternate drug delivery systems are necessary because many drugs degrade due to
enzymes or fail to be adequately absorbed into the body’s circulation system due to the
drug’s molecular size and/or charge. Injection and nanoneedle array have already been
developed, while current efforts include targeted delivery, where the drug is only
activated in a specific area of the body, and sustained release formulations, where the time
release of the drug is controlled. This research deals with the sustained release
formulation by way of polymeric micelles.

Figure 2: The molecular structure of PEG-Glu100-Leu100 polymer. Labelled in red is the
hydrophilic head of the polymer. Labelled in blue is the hydrophobic tail of the polymer.
The hydrophilic head of the PEG-Glu100-Leu100 polymer forms the outer shell of the
micelle when in contact with water. The hydrophobic tail forms the core, where the drug
should be encapsulated when the normal phase polymeric micelle is formed. PEG-Glu100Leu100 is soluble in THF, and forms a suspension in water.

Figure 4: Chemical structure of indometacin. The hydrophobic components are boxed in
blue.
The hydrophobic components of indometacin make this small molecule similar to the
polarity of the hydrophobic tail of the polymers being synthesized. Indometacin was
found to dissolve in THF, chloroform, and partially in water.

Finding an appropriate small drug molecule to closely match the polarity of the polymeric micelle’s hydrophobic core and the solubility properties of the drug is key in
creating this new drug delivery system. The appropriate drug will make the formation of the polymeric micelle around the drug more likely, thus creating the correct
environment for the drug delivery system to succeed. Indometacin was found to have similar properties to the PEG-Glu100-Leu100 polymer.

Figure 1: Normal Phase Polymeric Micelle
Normal phase micelles (Figure 1) are surfactant molecules dispersed in an
aqueous solution. Since the aqueous solution is polar, it can dissolve the
hydrophilic (polar) heads of the surfactant molecule, while simultaneously failing
to dissolve the hydrophobic (non-polar) tails of the surfactant molecule. This
causes the molecule to form a hydrophilic core around the hydrophobic tails’
center. Inverse phase micelles have the hydrophilic heads at the centre with the
hydrophobic tails extending outward.
This research is concerned with
synthesizing amphiphilic polymers that form normal phase micelles. Normal
phase polymeric micelles encapsulate drugs that usually fail to be adequately
absorbed and act as carriers within the body’s water-based circulatory system.
Advantages of polymeric micelles as a drug carriers are that they can deliver
these types of drugs to their desired site of action at concentrations that exceed
the normal amount, thus increasing their bioavailability.
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Dialysis is “the separation of small solute particles from colloid particles by
means of a semi-permeable membrane.” Dialysis was determined to be the best
known encapsulation method for this research. Since PEG-Glu100-Leu100 and
indometacin are soluble in THF, a solution can be made and placed into the semipermeable membrane bag. The idea is that when this bag is stirred in water, the
THF will flow out of the bag and the water will flow in. As the concentration of
water increases inside of the bag , PEG-Glu100-Leu100 starts to form micelles
around the indometacin molecules.

To create an environment like the human body, the encapsulated indometacin was
put in a buffer of pH 7.4 and stirred over an interval of time. At each interval, a
small amount was removed from the solution and analyzed using UV
Spectroscopy. A calibration curve of the concentration of indometacin in the
buffer vs. absorption at wavelength 408 nm was used to calibrate the data
gathered for the time interval release analysis, providing a graph of time vs.
concentration.
The time release was analyzed to show the progression of
indometacin released from the PEG-Glu100-Leu100 encapsulation. The time
release graph shows what is called a “burst release,” which means the drug is
rapidly released from the encapsulation.
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As shown in the NMR after dialysis, the indometacin was successfully
encapsulated by the PEG-Glu100-Leu100 and a time release profile was
gathered, thus providing preliminary information that this polymer has
potential in a new drug delivery system. Since this experiment did not
physically prove that an actual micelle was formed, further research will
have to be performed to provide this information. Also, more data can be
gathered using different types of polymers with the same methods. This
could lead to different time release profiles, as well as a better vehicle
polymer for the small molecule drug to be carried to a specific area. Once
more research has been performed on the polymeric micelle drug delivery
system, the next step would be to focus on specific small molecule drugs
and how to deliver them to a particular site in the body.

